The University of California and the University of Vienna on Monday convinced a U.S. appeals court to revive their bid for ...

About 150 people in Singapore have transthyretin amyloid cardiomyopathy. Read more at straitstimes.com. Read more at ...

At stake in the ongoing patent dispute over the gene-editing tool are rights to the most important new biotechnology of the ...

TwoStep Therapeutics, a biotechnology company developing innovative, first-in-class, multispecific targeted peptide conjugate therapies for solid tumors, will be presenting at the 2025 PEGS Boston ...

Yesterday, the US Court of Appeals for the Federal Circuit said scientists Jennifer Doudna and Emmanuelle Charpentier will ...

A federal appeals court said the patent office made legal errors in awarding foundational patents for CRISPR-Cas9 to the ...

Improvements in our understanding of the human genome, technological tools like artificial intelligence, and global ...

With potentially huge sums at stake, a federal court on Monday reinstated UC Berkeley’s legal claim seeking nationwide rights to develop and market gene editing, the transfer of genetic technology ...

Sweeping funding cuts are undermining the innovation that has been a central part of US economic strength for decades ...

Vienna, Austria – May 9th 2025 – Biomay, a leading manufacturer of recombinant proteins, today announced the commercial availability of its CRISPR/Cas9 nuclease, marking a significant addition to its ...

Those hoping the Court of Appeals for the Federal Circuit would finally resolve priority in the long-pending dispute between the University ...

A study of human tumor cells implanted in mice from the MacPherson Lab at Fred Hutch describes a new way to screen for the ...